CN115671053A - Preparation method of medicine-carrying powder containing porous mannitol - Google Patents
Preparation method of medicine-carrying powder containing porous mannitol Download PDFInfo
- Publication number
- CN115671053A CN115671053A CN202211399010.8A CN202211399010A CN115671053A CN 115671053 A CN115671053 A CN 115671053A CN 202211399010 A CN202211399010 A CN 202211399010A CN 115671053 A CN115671053 A CN 115671053A
- Authority
- CN
- China
- Prior art keywords
- mannitol
- solution
- porous
- preparation
- curcumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 title claims abstract description 117
- 229930195725 Mannitol Natural products 0.000 title claims abstract description 117
- 239000000594 mannitol Substances 0.000 title claims abstract description 117
- 235000010355 mannitol Nutrition 0.000 title claims abstract description 117
- 239000000843 powder Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 239000011246 composite particle Substances 0.000 claims abstract description 28
- 238000001035 drying Methods 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 15
- 238000007873 sieving Methods 0.000 claims abstract description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 106
- 239000000243 solution Substances 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 238000003756 stirring Methods 0.000 claims description 54
- 229940109262 curcumin Drugs 0.000 claims description 53
- 235000012754 curcumin Nutrition 0.000 claims description 53
- 239000004148 curcumin Substances 0.000 claims description 53
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 53
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 50
- 229960001680 ibuprofen Drugs 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 31
- 239000006228 supernatant Substances 0.000 claims description 23
- 238000004090 dissolution Methods 0.000 claims description 21
- 238000001694 spray drying Methods 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 235000019441 ethanol Nutrition 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 16
- 230000009286 beneficial effect Effects 0.000 claims description 11
- 238000007664 blowing Methods 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000013557 residual solvent Substances 0.000 claims description 9
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- 238000000889 atomisation Methods 0.000 claims description 8
- 238000005086 pumping Methods 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 abstract description 20
- 239000011148 porous material Substances 0.000 abstract description 13
- 238000009826 distribution Methods 0.000 abstract description 8
- 230000000052 comparative effect Effects 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 8
- 230000001476 alcoholic effect Effects 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 238000007605 air drying Methods 0.000 description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 4
- 241000723346 Cinnamomum camphora Species 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000005844 Thymol Substances 0.000 description 4
- 229960000846 camphor Drugs 0.000 description 4
- 229930008380 camphor Natural products 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960000790 thymol Drugs 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- -1 polyethylene pyrrolidone Polymers 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BBKFSSMUWOMYPI-UHFFFAOYSA-N gold palladium Chemical compound [Pd].[Au] BBKFSSMUWOMYPI-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a preparation method of medicine-carrying powder containing porous mannitol, relating to the technical field of medicines, and the preparation method of the medicine-carrying powder containing porous mannitol comprises the following steps: s1, preparing composite particles; preparing mannitol into a solution with the concentration of 5% -15%, preparing polyvinylpyrrolidone K30 into a solution with the concentration of 1% -10%, and mixing; s2, eluting polyvinylpyrrolidone K30 and drying to obtain porous mannitol; s3, preparing medicine carrying powder: adding porous mannitol, drying, and sieving to obtain medicine-carrying powder; the porous mannitol prepared by adding the polyvinylpyrrolidone K30 is mostly spherical or spheroidal, the roundness of the porous mannitol is high, the fluidity and the uniformity of materials are obviously improved, and the particle size distribution is more uniform; and a large number of pores are formed on the surface of the prepared porous mannitol, and the surface of the porous mannitol is of a sea urchin-shaped porous fluffy structure, so that the insoluble drug can be quickly released.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a preparation method of medicine-carrying powder containing porous mannitol.
Background
At present, the use of mannitol as a substitute for lactose in food and pharmaceutical formulations has increased significantly, and mannitol, which is the most common auxiliary material in tablet preparation in the pharmaceutical field, can be made into a substance with high porosity capable of improving the dissolution behavior of poorly soluble components by changing its structural properties; and because of the non-hygroscopic property and low water solubility of mannitol, mannitol is suitable to be used as an adsorption carrier, so a preparation technology is developed, and a porous auxiliary material with high specific surface area is produced by a template method; in addition, the porous material is a material which is developed rapidly in the current material science, and the research on the porous material discovers that the preparation method of the porous particles mainly comprises the steps of (1) selecting a porous carrier material; (2) chemically synthesizing and making holes; (3) preparing holes by using a pore-forming agent; (4) preparing holes by using a template agent; in the existing four preparation methods of porous particles, the first three methods are complex in preparation process, the porous carrier material in the method (1) is low in drug-loading rate, and the methods (2) and (3) can cause organic solvent residues; the preparation process of the method (4) is simple, and no additional working procedure is added on the basis of the original preparation process; at present, most of pore-forming agents are volatile substances or substances which are easy to generate and remove gas, and mainly comprise camphor, menthol, thymol, sodium bicarbonate, ammonium bicarbonate and the like; wherein, the camphor, the menthol and the thymol are insoluble in water, the pore-forming principle is that the camphor, the menthol and the thymol are slowly sublimated to generate pores and are difficult to be completely removed, and the camphor, the menthol and the thymol have pharmacological activity and can further cause the safety and effectiveness problems of the medicine; for pore-forming agents of sodium bicarbonate and ammonium bicarbonate, the two are decomposed to release gas for pore-forming, ammonia gas and sodium ion residues are generally generated by the method, on one hand, the environment is polluted, on the other hand, the excessive sodium ion residues are harmful to human bodies and are not beneficial to amplification production; the selection of the template is wide, the porous material prepared by the template has no harmful substance residue, the template can be removed, and the co-spray drying of the template is assisted to be the most common method for producing the porous material, so that the porous mannitol is prepared by adopting polyvinylpyrrolidone K30 (polyvinylpyrrolidone K30) as the template and adopting a spray drying process; compared with other template agents, on one hand, the surface tension of the polyvinylpyrrolidone K30 solution is smaller, and the influence of the polyvinylpyrrolidone K30 on the dissolution behavior is smaller; on the other hand, the polyvinyl pyrrolidone K30 can obviously reduce the wall sticking phenomenon in the spray drying process, thereby improving the yield.
Disclosure of Invention
In view of the above, the present invention provides a method for preparing a drug-loaded powder containing porous mannitol, which is characterized in that a polyethylene pyrrolidone K30 is used as a template agent, and a large number of pores are formed on the surface of the prepared porous mannitol, thereby facilitating the rapid release of insoluble drugs.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of medicine-carrying powder containing porous mannitol comprises the following steps:
s1: preparing composite particles: preparing mannitol into a clear transparent solution with the concentration of 5% -15%, then weighing polyvinyl pyrrolidone K30 to prepare a clear transparent solution with the concentration of 1% -10%, adding the prepared polyvinyl pyrrolidone K30 solution into the prepared mannitol solution, and stirring by magnetic force for at least 30min to uniformly mix the two solutions to obtain a clear transparent mixed solution; preparing composite particles by adopting a spray drying process;
s2: eluting polyvinyl pyrrolidone K30 and drying: adding absolute ethyl alcohol into the composite particles prepared in the S1, magnetically stirring for 12 hours at a stirring speed of 400r/min, centrifuging, removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12 hours at a stirring speed of 400r/min, centrifuging, removing supernatant, and drying the precipitate at 40 ℃ by blowing air to constant weight to obtain porous mannitol;
s3: preparing medicine-carrying powder: dissolving curcumin and ibuprofen in two groups of absolute ethyl alcohol in a one-to-one correspondence mode respectively, wherein the mass ratio of the curcumin to the ibuprofen is 1:1, the volume ratio of the mass of the curcumin to the absolute ethyl alcohol is 10:3mg/mL; and (3) performing ultrasonic treatment and vortexing for 30min to fully dissolve the curcumin and the ibuprofen, respectively adding the porous mannitol obtained in the step (S2) into an alcoholic solution in which the curcumin is dissolved and an alcoholic solution in which the ibuprofen is dissolved after the curcumin and the ibuprofen are completely dissolved, stirring and centrifuging, removing supernate, drying, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
As a preferred embodiment: the surface of the porous mannitol obtained in S2 is in a porous fluffy structure which is beneficial to the dissolution of insoluble medicines.
As a preferred scheme: the technological parameters for preparing the composite particles by spray drying in the S1 are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar.
As a preferred embodiment: the concentration of the prepared mannitol solution in the S1 is 10%.
As a preferred embodiment: the concentration of the prepared polyvinylpyrrolidone K30 solution in the S1 is 1%, 3% or 5%.
As a preferred embodiment: the volume ratio of the weight of the composite particles in the S2 to the absolute ethyl alcohol is 1:10g/mL.
As a preferred embodiment: conditions of centrifugation in S2: the rotating speed is 5000r/min, and the centrifugation time is 10min.
As a preferred scheme: the conditions of stirring and centrifugation in S3: stirring the solution on a magnetic stirrer at the rotating speed of 300r/min for 7 hours, and centrifuging the solution at the rotating speed of 5000r/min for 10 minutes.
As a preferred embodiment: after removing the supernatant in S3, the sample was purged with nitrogen for 4 hours to remove the residual solvent.
As a preferred embodiment: drying conditions in the S3: the samples were dried in an oven at 40 ℃.
Compared with the prior art, the method has obvious advantages and beneficial effects, and concretely, according to the technical scheme, the polyvinylpyrrolidone K30 is selected as the template agent, so that on one hand, the polyvinylpyrrolidone K30 is easily dissolved in ethanol and is easily removed through ethanol elution, and a porous material with high porosity can be obtained; secondly, the addition of the polyethylene pyrrolidone K30 is beneficial to improving the wall sticking phenomenon in the spray drying process and improving the sample yield; on the other hand, the porous mannitol prepared by adding the polyvinylpyrrolidone K30 is mostly in a spherical or spheroidal structure, the roundness of the porous mannitol is high, the sphericity is better, the fluidity and the uniformity of materials are obviously improved, and the particle size distribution is more uniform; and a large number of pores are formed on the surface of the prepared porous mannitol, and the surface of the porous mannitol is of a sea urchin-shaped porous fluffy structure, so that the insoluble drug can be quickly released.
To more clearly illustrate the structural features and effects of the present invention, the following detailed description is given with reference to the accompanying drawings and specific embodiments.
Drawings
FIG. 1 is a scanning electron micrograph of mannitol provided by a control group according to the present invention;
FIG. 2 is a scanning electron micrograph of mannitol provided in comparative example 1 of the present invention;
FIG. 3 is a scanning electron micrograph of mannitol provided in comparative example 2 of the present invention;
FIG. 4 is a scanning electron micrograph of the porous mannitol provided in example 1 of the present invention;
FIG. 5 is a scanning electron micrograph of the porous mannitol provided in example 2 of the present invention;
FIG. 6 is a scanning electron micrograph of polyporous mannitol provided in example 3 of the present invention;
fig. 7 is a drug release behavior characterization graph of drug-loaded powders formed after curcumin is loaded on porous mannitol provided in examples 1 to 3 and comparative examples 1, 2 and a control group;
fig. 8 is a drug release behavior characterization diagram of drug-loaded powders formed after ibuprofen is loaded on porous mannitol provided in examples 1 to 3 and comparative examples 1, 2 and a control group.
Detailed Description
A preparation method of medicine-carrying powder containing porous mannitol comprises the following steps:
s1: preparing composite particles: preparing mannitol into a clear transparent solution with the concentration of 5% -15%, then weighing polyvinylpyrrolidone K30 to prepare a clear transparent solution with the concentration of 1% -10%, adding the prepared polyvinylpyrrolidone K30 solution into the prepared mannitol solution, and stirring by magnetic force for at least 30min to uniformly mix the two solutions to obtain a clear transparent mixed solution; the composite particles are prepared by adopting a spray drying process, and the spray drying process comprises the following process parameters: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar;
s2: eluting polyvinyl pyrrolidone K30 and drying: adding absolute ethyl alcohol into the composite particles prepared in the step S1, wherein the volume ratio of the weight of the composite particles to the absolute ethyl alcohol is 1:10g/mL; stirring for 12 hours by magnetic force, wherein the stirring speed is 400r/min; centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12h at the stirring speed of 400r/min, and centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, and air drying the precipitate at 40 deg.C to constant weight to obtain porous mannitol; the surface of the obtained porous mannitol is in a porous fluffy structure which is beneficial to the dissolution of insoluble medicines;
s3: preparing medicine-carrying powder: dissolving curcumin and ibuprofen in two groups of absolute ethyl alcohol in a one-to-one correspondence mode respectively, wherein the mass ratio of the curcumin to the ibuprofen is 1:1, the volume ratio of the mass of the curcumin to the absolute ethyl alcohol is 10:3mg/mL; performing ultrasonic treatment and vortexing for 30min to fully dissolve curcumin and ibuprofen, respectively adding the porous mannitol obtained in S2 into an alcoholic solution in which curcumin is dissolved and an alcoholic solution in which ibuprofen is dissolved after curcumin and ibuprofen are completely dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at the rotating speed of 300r/min for 7 hours, and centrifuging the solution at the rotating speed of 5000r/min for 10min; and removing the supernatant, blowing nitrogen for 4 hours to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Example 1
A preparation method of medicine-carrying powder containing porous mannitol comprises the following steps:
s1: preparing composite particles: preparing mannitol into a clear and transparent solution with the concentration of 10%, then weighing polyvinyl pyrrolidone K30 to prepare a clear and transparent solution with the concentration of 1%, adding the prepared polyvinyl pyrrolidone K30 solution into the prepared mannitol solution, and magnetically stirring for at least 30min to uniformly mix the two solutions to obtain a clear and transparent mixed solution; the composite particles are prepared by adopting a spray drying process, and the spray drying process parameters are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar;
s2: eluting polyvinyl pyrrolidone K30 and drying: adding absolute ethyl alcohol into the composite particles prepared in the S1, wherein the volume ratio of the weight of the composite particles to the absolute ethyl alcohol is 1:10g/mL; stirring for 12 hours by magnetic force, wherein the stirring speed is 400r/min; centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12h at the stirring speed of 400r/min, and centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, and air drying the precipitate at 40 deg.C to constant weight to obtain porous mannitol; the surface of the obtained porous mannitol is in a porous fluffy structure which is beneficial to the dissolution of insoluble medicines;
s3: preparing medicine-carrying powder: dissolving 100mg of curcumin and 100mg of ibuprofen in two groups of 30mL of absolute ethyl alcohol respectively in a one-to-one correspondence manner; and (3) carrying out ultrasonic treatment and vortex for 30min to fully dissolve the curcumin and the ibuprofen, after the curcumin and the ibuprofen are completely dissolved, respectively adding 5g of porous mannitol obtained in the step (S2) into an alcohol solution in which the curcumin is dissolved and an alcohol solution in which the ibuprofen is dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at a rotating speed of 300r/min for 7 hours, and centrifuging the solution at a rotating speed of 5000r/min for 10min; and removing the supernatant, blowing nitrogen for 4 hours to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Example 2
A preparation method of medicine-carrying powder containing porous mannitol comprises the following steps:
s1: preparing composite particles: preparing mannitol into a clear and transparent solution with the concentration of 10%, then weighing polyvinylpyrrolidone K30 to prepare a clear and transparent solution with the concentration of 3%, adding the prepared polyvinylpyrrolidone K30 solution into the prepared mannitol solution, and performing magnetic stirring for at least 30min to uniformly mix the two solutions to obtain a clear and transparent mixed solution; the composite particles are prepared by adopting a spray drying process, and the spray drying process parameters are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar;
s2: eluting polyvinyl pyrrolidone K30 and drying: adding absolute ethyl alcohol into the composite particles prepared in the S1, wherein the volume ratio of the weight of the composite particles to the absolute ethyl alcohol is 1:10g/mL; stirring for 12 hours by magnetic force, wherein the stirring speed is 400r/min; centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12h at the stirring speed of 400r/min, and centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, and air drying the precipitate at 40 deg.C to constant weight to obtain porous mannitol; the surface of the obtained porous mannitol is in a porous fluffy structure which is beneficial to the dissolution of insoluble medicines;
s3: preparing medicine-carrying powder: dissolving 100mg of curcumin and 100mg of ibuprofen in two groups of 30mL of absolute ethyl alcohol respectively in a one-to-one correspondence manner; and (3) performing ultrasonic treatment and vortex for 30min to fully dissolve the curcumin and the ibuprofen, after the curcumin and the ibuprofen are completely dissolved, respectively adding 5g of porous mannitol obtained in the step (S2) into an alcohol solution in which the curcumin is dissolved and an alcohol solution in which the ibuprofen is dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at the rotating speed of 300r/min for 7 hours, and centrifuging the solution at the rotating speed of 5000r/min for 10min; removing the supernatant, blowing the sample with nitrogen for 4h to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Example 3
A preparation method of medicine-carrying powder containing porous mannitol comprises the following steps:
s1: preparing composite particles: preparing mannitol into a clear and transparent solution with the concentration of 10%, then weighing polyvinylpyrrolidone K30 to prepare a clear and transparent solution with the concentration of 5%, adding the prepared polyvinylpyrrolidone K30 solution into the prepared mannitol solution, and performing magnetic stirring for at least 30min to uniformly mix the two solutions to obtain a clear and transparent mixed solution; the composite particles are prepared by adopting a spray drying process, and the spray drying process parameters are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar;
s2: eluting polyvinyl pyrrolidone K30 and drying: adding absolute ethyl alcohol into the composite particles prepared in the step S1, wherein the volume ratio of the weight of the composite particles to the absolute ethyl alcohol is 1:10g/mL; magnetically stirring for 12 hours at the stirring speed of 400r/min; centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12 hours at the stirring speed of 400r/min, centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, and air-drying the precipitate at 40 deg.C to constant weight to obtain porous mannitol; the surface of the obtained porous mannitol is in a porous fluffy structure which is beneficial to the dissolution of insoluble medicines;
s3: preparing medicine-carrying powder: respectively dissolving 100mg of curcumin and 100mg of ibuprofen in two groups of 30mL of anhydrous ethanol in a one-to-one correspondence manner; and (3) carrying out ultrasonic treatment and vortex for 30min to fully dissolve the curcumin and the ibuprofen, after the curcumin and the ibuprofen are completely dissolved, respectively adding 5g of porous mannitol obtained in the step (S2) into an alcohol solution in which the curcumin is dissolved and an alcohol solution in which the ibuprofen is dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at a rotating speed of 300r/min for 7 hours, and centrifuging the solution at a rotating speed of 5000r/min for 10min; removing the supernatant, blowing the sample with nitrogen for 4h to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Comparative example 1
A preparation method of medicine-carrying powder comprises the following steps:
s1: preparing particles: preparing clear and transparent solution with concentration of 10% with mannitol, and magnetically stirring for at least 30min; the particles are prepared by adopting a spray drying process, and the spray drying process parameters are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar;
s2: and (3) drying: drying the particles prepared in the step S1 at 40 ℃ by blowing air until the weight is constant to obtain mannitol;
s3: preparing medicine-carrying powder: dissolving 100mg of curcumin and 100mg of ibuprofen in two groups of 30mL of absolute ethyl alcohol respectively in a one-to-one correspondence manner; and (3) carrying out ultrasonic treatment and vortex for 30min to fully dissolve the curcumin and the ibuprofen, after the curcumin and the ibuprofen are completely dissolved, respectively adding 5g of mannitol obtained in the step (S2) into an alcohol solution in which the curcumin is dissolved and an alcohol solution in which the ibuprofen is dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at a rotating speed of 300r/min for 7 hours, and centrifuging the solution at a rotating speed of 5000r/min for 10min; removing the supernatant, blowing the sample with nitrogen for 4h to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Comparative example 2
A preparation method of medicine-carrying powder comprises the following steps:
s1: preparing particles: preparing clear and transparent solution with concentration of 10% with mannitol, and magnetically stirring for at least 30min; the particles are prepared by adopting a spray drying process, and the spray drying process parameters are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar;
s2: and (3) eluting and drying: adding absolute ethyl alcohol into the particles prepared in the step S1, wherein the volume ratio of the weight of the particles to the added absolute ethyl alcohol is 1:10g/mL; magnetically stirring for 12 hours at the stirring speed of 400r/min; centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12h at the stirring speed of 400r/min, and centrifuging: the rotating speed is 5000r/min, and the centrifugation time is 10min; removing supernatant, and air-drying the precipitate at 40 deg.C to constant weight to obtain mannitol;
s3: preparing medicine-carrying powder: respectively dissolving 100mg of curcumin and 100mg of ibuprofen in two groups of 30mL of anhydrous ethanol in a one-to-one correspondence manner; and (3) carrying out ultrasonic treatment and vortex for 30min to fully dissolve the curcumin and the ibuprofen, after the curcumin and the ibuprofen are completely dissolved, respectively adding 5g of mannitol obtained in the step (S2) into an alcohol solution in which the curcumin is dissolved and an alcohol solution in which the ibuprofen is dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at a rotating speed of 300r/min for 7 hours, and centrifuging the solution at a rotating speed of 5000r/min for 10min; removing the supernatant, blowing the sample with nitrogen for 4h to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Control group
A preparation method of medicine-carrying powder comprises the following steps:
s1: preparing medicine-carrying powder: dissolving 100mg of curcumin and 100mg of ibuprofen in two groups of 30mL of absolute ethyl alcohol respectively in a one-to-one correspondence manner; performing ultrasonic treatment and vortexing for 30min to fully dissolve curcumin and ibuprofen, after the curcumin and ibuprofen are completely dissolved, respectively adding 5g of mannitol into an alcoholic solution in which the curcumin is dissolved and an alcoholic solution in which the ibuprofen is dissolved, stirring and centrifuging: stirring the solution on a magnetic stirrer at the rotating speed of 300r/min for 7 hours, and centrifuging the solution at the rotating speed of 5000r/min for 10min; removing the supernatant, blowing the sample with nitrogen for 4h to remove the residual solvent, drying the sample in an oven at 40 ℃, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
Effect example 1
The structures of the porous mannitol prepared in examples 1 to 3 and the mannitol obtained in comparative examples 1, 2 and control were characterized: equal amounts of the porous mannitol prepared in examples 1 to 3 and the mannitol obtained in comparative example 1, comparative example 2 and control were placed on an aluminum sample tray with a conductive adhesive, and then a gold palladium coating was applied to the porous mannitol prepared in examples 1 to 3 and the mannitol obtained in comparative example 1, comparative example 2 and control, respectively, to produce a conductive layer, and observed under a scanning electron microscope at different magnifications under an accelerating voltage of 20KV, and the results were shown in fig. 1 to 6.
As can be seen from fig. 1-6: compared with the control group, the comparative example 1 and the comparative example 2, the particles of the porous mannitol prepared in the example 1, the example 2 and the example 3 are in a sphere-like shape, and the surface of the porous mannitol is in a sea urchin-shaped porous fluffy structure; in contrast, the mannitol particles prepared in comparative example 1 and comparative example 2 have rounded spherical shapes and the surfaces of the mannitol particles do not have a porous fluffy structure, as compared to the control group, example 1, example 2 and example 3.
Effect example 2
The fluidity (Carr index, hausner ratio, and angle of repose), particle size distribution (uniformity), and specific surface area of the porous mannitol prepared in example 1, example 2, and example 3, and the mannitol obtained in comparative example 1, comparative example 2, and the control group were characterized, and the results are shown in Table 1; the dissolution behavior of the drug-loaded powders obtained in example 1, example 2, example 3, comparative example 1, comparative example 2 and control group was measured to evaluate the porous mannitol drug release behavior, and the results are shown in fig. 7 and fig. 8.
Table 1: characterization of the relevant Properties of the mannitol samples (X. + -. SD, n = 3)
As can be seen from Table 1: the BET-characterized surface areas of the porous mannitol prepared in example 1, example 2 and example 3 were increased by 231.8%, 443.8% and 273.7%, respectively, compared to the control group; BJH-characterized surface areas increased by 114.4%, 285.4% and 15.8%, respectively; the BET-characterized surface areas of the porous mannitol prepared in example 1, example 2 and example 3 were increased by 119.5%, 259.7% and 97.3%, respectively, compared to comparative example 1; BJH-characterized surface areas increased by 94.5%, 249.7% and 5.1%, respectively; the BET-characterized surface areas of the porous mannitol prepared in example 1, example 2 and example 3 were increased by 69.4%, 177.6% and 52.3%, respectively, compared to comparative example 2; BJH-characterized surface areas increased by 86.7%, 234.8% and 0.6%, respectively; the above results all show that example 1, example 2 and example 3 successfully produced porous mannitol.
The Carl indexes of the porous mannitol prepared in example 1, example 2 and example 3 were increased by 56.4%, 46.1% and 35.9%, respectively, the Hausnib was increased by 24.7%, 19.3% and 14.5%, respectively, and the angle of repose was increased by 22.2%, 18.9% and 17.7%, respectively, compared to the control group; compared with comparative example 1, the Carl indexes of the porous mannitol prepared in example 1, example 2 and example 3 were increased by 22.0%, 14.0% and 6.0%, respectively, the Hausnib was increased by 12.3%, 7.4% and 3.0%, respectively, and the angle of repose was increased by 4.4%, 1.5% and 0.5%, respectively; compared with comparative example 2, the Carl index of the porous mannitol prepared in example 1, example 2 and example 3 is respectively reduced by 10.0%, 15.9% and 21.8%, the Haosnabis is respectively reduced by 7.6%, 11.6% and 15.2%, and the angle of repose is respectively reduced by 0.5% and 1.5% except for example 1; the above results all indicate that the fluidity of the porous mannitol prepared in examples 1 to 3 is significantly improved.
The uniformity values of the particle size distribution of the porous mannitol prepared in example 1, example 2 and example 3 were increased by 69.9%, 47.3% and 54.7%, respectively, compared to the control group; the particle size distribution uniformity values of the porous mannitol prepared in example 2 and example 3 were reduced by 5.1% and 0.3%, respectively, compared to comparative example 1; the particle size distribution uniformity values of the porous mannitol prepared in example 1, example 2 and example 3 were decreased by 22.3%, 32.7% and 29.2%, respectively, compared to comparative example 2; the above results all show that the particle size distribution of the porous mannitol prepared in examples 1 to 3 is more uniform.
As can be seen from fig. 7 and 8: for curcumin-loaded drug-loaded powders; the difference between the dissolution rate and the balance dissolution amount of the first, the comparative examples 1, the comparative examples 2 and the control group is not changed greatly; secondly, at 30min, the cumulative dissolution percentage of the comparative example 1, the comparative example 2 and the control group is still less than 30%, but the cumulative dissolution percentage of the example 1, the example 2 and the example 3 reaches 50% -70%; at 90min, the cumulative dissolution percentage of comparative example 1, comparative example 2 and control was around 30%, but the cumulative dissolution percentage of example 1, example 2 and example 3 could reach around 70%.
For ibuprofen loaded drug loaded powder: the difference of the dissolution rate and the balance dissolution amount of the first, the comparative example 1, the comparative example 2 and the control group is not large; secondly, at 20min, the cumulative dissolution percentage of the comparative example 1, the comparative example 2 and the control group is still less than 10%, but the cumulative dissolution percentage of the example 1, the example 2 and the example 3 reaches 25% -40%; at 90min, the cumulative dissolution percentage of the comparative examples 1, 2 and the control group is still less than 30%, but the cumulative dissolution percentage of the examples 1, 2 and 3 can reach about 70%; the results all show that compared with the control group, the comparative example 1 and the comparative example 2, the drug release rate and the balance release amount of the porous mannitol drug-loaded powder prepared in the examples 1, 2 and 3 are obviously increased, and the drug release behavior is better.
The design of the invention is characterized in that in the prior art, ammonia gas or sodium ion residues are generated and generated by adopting ammonium bicarbonate and sodium bicarbonate to generate pores, so that the method is not beneficial to amplification production; secondly, the commonly used templates for preparing the high-porosity mannitol in the prior art are citric acid and sucrose, and for the two templates, the removal effect is poor through ethanol elution, and the obtained porous material has low porosity; the method selects the polyvinylpyrrolidone K30 as a template agent, on one hand, the polyvinylpyrrolidone K30 is easy to dissolve in ethanol and is easy to remove by ethanol elution, and a porous material with high porosity can be obtained; secondly, the addition of the polyethylene pyrrolidone K30 is beneficial to improving the wall sticking phenomenon in the spray drying process and improving the sample yield; on the other hand, the porous mannitol prepared by adding the polyvinylpyrrolidone K30 is mostly in a spherical or spheroidal structure, the roundness of the porous mannitol is high, the sphericity is better, the fluidity and the uniformity of materials are obviously improved, and the particle size distribution is more uniform; a large number of pores are formed on the surface of the prepared porous mannitol, and the surface of the porous mannitol is of a sea urchin-shaped porous fluffy structure, so that the insoluble drug can be quickly released; the polyvinyl pyrrolidone K30 is added in the stage of preparing the composite particles, and the original preparation process is not added.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the technical scope of the present invention, so that any minor modifications, equivalent changes and modifications made to the above embodiment according to the technical spirit of the present invention are within the technical scope of the present invention.
Claims (10)
1. A preparation method of medicine-carrying powder containing porous mannitol, which is characterized in that; the method comprises the following steps:
s1: preparing composite particles: preparing mannitol into a clear transparent solution with the concentration of 5% -15%, then weighing polyvinylpyrrolidone K30 to prepare a clear transparent solution with the concentration of 1% -10%, adding the prepared polyvinylpyrrolidone K30 solution into the prepared mannitol solution, and stirring by magnetic force for at least 30min to uniformly mix the two solutions to obtain a clear transparent mixed solution; preparing composite particles by adopting a spray drying process;
s2: eluting polyvinyl pyrrolidone K30 and drying: adding absolute ethyl alcohol into the composite particles prepared in the S1, magnetically stirring for 12 hours at a stirring speed of 400r/min, centrifuging, removing supernatant, adding absolute ethyl alcohol again, magnetically stirring for 12 hours at a stirring speed of 400r/min, centrifuging, removing supernatant, and drying the precipitate at 40 ℃ by blowing air to constant weight to obtain porous mannitol;
s3: preparing medicine-carrying powder: dissolving curcumin and ibuprofen in two groups of absolute ethyl alcohol in a one-to-one correspondence mode respectively, wherein the mass ratio of the curcumin to the ibuprofen is 1:1, the volume ratio of the mass of the curcumin to the absolute ethyl alcohol is 10:3mg/mL; and (3) performing ultrasonic treatment and vortex for 30min to fully dissolve the curcumin and the ibuprofen, respectively adding the porous mannitol obtained in the step (S2) into an alcohol solution in which the curcumin is dissolved and an alcohol solution in which the ibuprofen is dissolved after the curcumin and the ibuprofen are completely dissolved, stirring and centrifuging, removing supernate, drying, and sieving with a 50-mesh sieve to obtain curcumin-loaded powder and ibuprofen-loaded powder.
2. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; the surface of the porous mannitol obtained in S2 is in a porous fluffy structure which is beneficial to the dissolution of insoluble medicines.
3. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; the technological parameters for preparing the composite particles by spray drying in the S1 are as follows: the air inlet temperature is 150 ℃, the material pumping speed is 3-3.5mL/min, and the atomization pressure is 45bar.
4. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; the concentration of the prepared mannitol solution in the S1 is 10%.
5. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; the concentration of the prepared polyvinyl pyrrolidone K30 solution in the S1 is 1%, 3% or 5%.
6. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; the volume ratio of the weight of the composite particles in the S2 to the absolute ethyl alcohol is 1:10g/mL.
7. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; conditions of centrifugation in S2: the rotating speed is 5000r/min, and the centrifugation time is 10min.
8. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; the conditions of stirring and centrifugation in S3: stirring the solution on a magnetic stirrer at the rotating speed of 300r/min for 7 hours, and centrifuging the solution at the rotating speed of 5000r/min for 10 minutes.
9. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; after removing the supernatant in S3, the sample was purged with nitrogen for 4 hours to remove the residual solvent.
10. The preparation method of the drug-loaded powder containing porous mannitol according to claim 1; it is characterized in that; drying conditions in the S3: the samples were dried in an oven at 40 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211399010.8A CN115671053A (en) | 2022-11-09 | 2022-11-09 | Preparation method of medicine-carrying powder containing porous mannitol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211399010.8A CN115671053A (en) | 2022-11-09 | 2022-11-09 | Preparation method of medicine-carrying powder containing porous mannitol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671053A true CN115671053A (en) | 2023-02-03 |
Family
ID=85050400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211399010.8A Pending CN115671053A (en) | 2022-11-09 | 2022-11-09 | Preparation method of medicine-carrying powder containing porous mannitol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671053A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026832A1 (en) * | 2000-03-29 | 2003-02-06 | Erik Labergerie | Pulverulent mannitol and process for preparing it |
| US20030114717A1 (en) * | 2001-12-13 | 2003-06-19 | Merck Patent Gmbh | Process for the preparation of ss-mannitol for direct compression |
| CN109481690A (en) * | 2019-01-23 | 2019-03-19 | 谭淞文 | A kind of Novel microcrystalline mannitol pharmaceutic adjuvant |
| CN112274485A (en) * | 2020-12-29 | 2021-01-29 | 江西中医药大学 | Three-dimensional porous lactose particle and preparation method and application thereof |
-
2022
- 2022-11-09 CN CN202211399010.8A patent/CN115671053A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026832A1 (en) * | 2000-03-29 | 2003-02-06 | Erik Labergerie | Pulverulent mannitol and process for preparing it |
| US20030114717A1 (en) * | 2001-12-13 | 2003-06-19 | Merck Patent Gmbh | Process for the preparation of ss-mannitol for direct compression |
| CN109481690A (en) * | 2019-01-23 | 2019-03-19 | 谭淞文 | A kind of Novel microcrystalline mannitol pharmaceutic adjuvant |
| CN112274485A (en) * | 2020-12-29 | 2021-01-29 | 江西中医药大学 | Three-dimensional porous lactose particle and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 姚静: "《药用辅料应用指南》", 中国医药科技出版社, pages: 245 - 247 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Infanger et al. | Powder bed 3D-printing of highly loaded drug delivery devices with hydroxypropyl cellulose as solid binder | |
| CA2126864A1 (en) | Pharmaceutical compositions containing nifedipine and process for the preparation thereof | |
| Chen et al. | Generation of porous poly-L-lactide microspheres by emulsion-combined precipitation with a compressed CO 2 antisolvent process | |
| JPH02149513A (en) | Low-solubility drug carried by polymer base in the form suited for improvement of solubility and its manufacture | |
| CN112274485B (en) | Three-dimensional porous lactose particle and preparation method and application thereof | |
| CN115671053A (en) | Preparation method of medicine-carrying powder containing porous mannitol | |
| Takeuchi et al. | Controlled release theophylline tablet with acrylic polymers prepared by spray-drying technique in aqueous system | |
| Zhang et al. | Effect of spheronization technique on drug release from uncoated beads | |
| JP2003501378A (en) | Method for coating particles and particles produced by the method | |
| CA2954287C (en) | Methods of preparing inhalable micronized insulin for pulmonary delivery | |
| CN115068421A (en) | Ruogeli nanosuspension and preparation method and application thereof | |
| CN102697738A (en) | Preparation method of porous microspheres by carbon dioxide fluid anti-solvent method | |
| CN116172966A (en) | Nanocrystalline solid dispersion spheroidized particles and preparation method and application thereof | |
| Young et al. | Properties of drug-containing spherical pellets produced by a hot-melt extrusion and spheronization process | |
| KR101367775B1 (en) | Uniformly micro-structured particles for solubilization of low-melting insoluble drugs, methods and apparatus for preparing the same | |
| KR20120034264A (en) | Oral solid preparation composition containing silymarin using membrane emulsification technique, and its production method | |
| CN106344530A (en) | Sorafenib composition and preparation method thereof | |
| Yu et al. | Oral fast-dissolving DDD fabricated using 3DP | |
| Bagratashvili et al. | Supercritical fluid fabrication of components for a sustained-release injectable risperidone dose form | |
| CN104771380A (en) | Tacrolimus capsule capable of being rapidly dissolved out | |
| CN104706598B (en) | A kind of development and its application of Cryptotanshinone slow-release solid dispersion pellet | |
| CN114247393B (en) | Magnetic polymer microsphere and preparation method and application thereof | |
| CN108553445A (en) | A kind of preparation method of taxol powder spray | |
| CN110585159B (en) | Tablet containing sirolimus | |
| Türk et al. | Stabilization of pharmaceutical substances by the rapid expansion of supercritical solutions (RESS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230203 |
|
| RJ01 | Rejection of invention patent application after publication |